Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Do Hedge Funds Love Glaukos Corp (GKOS)?

Page 1 of 2

The worries about the economic slowdown in China and the ongoing uncertainty about the path of interest-rate increases triggered several waves of equity sell-offs during the third quarter. Of course, most hedge funds and other asset managers had to stomach substantial losses during the bloody three-month period, which might have caused some to consider fleeing the U.S. equity markets. Interestingly, smaller-cap stocks registered higher losses than large-capitalization stocks during the September quarter, suggesting that institutional investors heavily discarded seemingly riskier equities amid high uncertainty and turmoil. In fact, the Russell 2000 Index lost 11.9% in the third quarter, while the Standard and Poor’s 500 benchmark declined a mere 6.4%. This article will lay out and discuss the hedge fund and institutional investor sentiment towards Glaukos Corp (NYSE:GKOS).

Glaukos Corp (NYSE:GKOS) investors should be aware of a decrease in hedge fund sentiment in recent months. The hedge funds we track at Insider Monkey echoed a similar sentiment as that of the shares of the company, which dropped 16.53% throughout the last quarter. This demands a further coverage of hedge funds that held positions in Glaukos Corp (NYSE:GKOS) despite this drop.

The level and the change in hedge fund popularity aren’t the only variables you need to analyze to decipher hedge funds’ perspectives. A stock may witness a boost in popularity, but it may still be less popular than similarly priced stocks. That’s why at the end of this article we will examine companies such as GasLog Ltd (NYSE:GLOG), Par Pacific Holdings, Inc. (NYSEMKT:PARR), and American Railcar Industries, Inc. (NASDAQ:ARII) to gather more data points.

Follow Glaukos Corp
Trade (GKOS) Now!

At the moment, there are dozens of gauges market participants have at their disposal to analyze publicly traded companies. A couple of the most under-the-radar gauges are hedge fund and insider trading interest. We have shown that, historically, those who follow the best picks of the top investment managers can trounce their index-focused peers by a solid margin (see the details here).

Keeping this in mind, we’re going to view the latest action regarding Glaukos Corp (NYSE:GKOS).

Hedge fund activity in Glaukos Corp (NYSE:GKOS)

Heading into Q4, a total of 6 of the hedge funds tracked by Insider Monkey held long positions in this stock, a drop of 33% from the second quarter. With the smart money’s positions undergoing their usual ebb and flow, there exists a select group of key hedge fund managers who were boosting their stakes meaningfully (or already accumulated large positions).

According to Insider Monkey’s hedge fund database, OrbiMed Advisors, managed by Samuel Isaly, holds the biggest position in Glaukos Corp (NYSE:GKOS). OrbiMed Advisors has a $70.1 million position in the stock, comprising 0.7% of its 13F portfolio. The second most bullish fund manager is Adage Capital Management, led by Phill Gross and Robert Atchinson, holding a $4.2 million position; the fund has less than 0.1% of its 13F portfolio invested in the stock. Other hedge funds and institutional investors that are bullish include Richard Driehaus’ Driehaus Capital, Israel Englander’s Millennium Management, and Ken Griffin’s Citadel Investment Group.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!